Expression of heparanase in renal cell carcinomas: Implications for tumor invasion and prognosis

Clinical Cancer Research

Volumn 14, Issue 19, 2008, Pages 6055-6061

  Mikami, Shuji ^a   Oya, Mototsugu ^b   Shimoda, Masayuki ^b   Mizuno, Ryuichi ^b   Ishida, Masaru ^b   Kosaka, Takeo ^b   Mukai, Makio ^a   Nakajima, Motowo ^c   Okada, Yasunori ^b  

^a KEIO UNIVERSITY HOSPITAL   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c New Business and Technology Transfer   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARANASE; MATRIGEL; MESSENGER RNA; SMALL INTERFERING RNA; BETA GLUCURONIDASE;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CELL SURFACE; CONTROLLED STUDY; DISTANT METASTASIS; DOWN REGULATION; ENZYME REGULATION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; BIOSYNTHESIS; CELL MEMBRANE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENE SILENCING; KIDNEY TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PHYSIOLOGY; TUMOR CELL LINE;

AGED; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MEMBRANE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLUCURONIDASE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROGNOSIS;

EID: 58149161758     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0750     Document Type: Article

References (24)

1. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. World Health Organization classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs. Lyon: IARC Press; 2005.
2. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002;20:4559-66.
3. Engbring JA, Kleinman HK. The basement membrane matrix in malignancy. J Pathol 2003;200:465-70.
4. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70.
5. Kugler A, Hemmerlein B, Thelen P, et al. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 1998;160:1914-8.
6. Lein M, Jung K, Laube C, et al. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. Int J Cancer 2000;85:801-4.
7. Timar J, Lapis K, Dudas J, et al. Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer. Semin Cancer Biol 2002;12:173-86.
8. El-Assal ON, Yamanoi A, Ono T, et al. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res 2001;7:1299-305.
9. Gohji K, Okamoto M, Kitazawa S, et al. Heparanase protein and gene expression in bladder cancer. J Urol 2001;166:1286-90.
10. Mikami S, Ohashi K, Usui Y, et al. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas. Jpn J Cancer Res 2001;92:1062-73.
11. Vlodavsky I, Friedmann Y, Elkin M, et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999;5:793-802.
12. (UICC) IUAC. TNM classification of malignant tumours. In: Sobin L, Wittekind C, editors. New York: Wiley-Liss; 1997.
13. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
14. Mikami S, Oya M, Mizuno R, et al. Expression of Ets-1 in human clear cell renal cell carcinomas: implications for angiogenesis. Cancer Sci 2006;97:875-82.
15. Wang Z, Banerjee S, Li Y, et al. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-κB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 2006;66:2778-84.
16. Uno F, Fujiwara T, Takata Y, et al. Antisense-mediated suppression of human heparanase gene expression inhibits pleural dissemination of human cancer cells. Cancer Res 2001;61:7855-60.
17. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003;27:612-24.
18. Vreys V, David G. Mammalian heparanase: what is the message? J Cell Mol Med 2007;11:427-52.
19. Petrella BL, Brinckerhoff CE. Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase. Mol Cancer 2006;5:66.
20. Miyata Y, Iwata T, Ohba K, et al. Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in renal cell carcinoma: prognostic implications and clinical significance for invasion and metastasis. Clin Cancer Res 2006;12:6998-7003.
21. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001;108:341-7.
22. Sasisekharan R, Shriver Z, Venkataraman G, et al. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2002;2:521-8.
23. Parish CR, Freeman C, Brown KJ, et al. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 1999;59:3433-41.
24. Basche M, Gustafson DL, Holden SN, et al. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res 2006;12:5471-80.